Breast cancer survivors face a roughly 17% higher chance of developing another cancer compared to women with no cancer history, yet current survivorship guidelines focus almost entirely on watching for breast cancer recurrence. A new study from Fred Hutch Cancer Center suggests that annual blood tests designed to detect multiple cancers at once could fill a critical gap in survivor care, particularly for those with hormone receptor-negative breast cancers.

Why Are Breast Cancer Survivors at Higher Risk for New Cancers?

Surviving breast cancer is a major achievement, but the journey doesn't end with treatment. Breast cancer survivors are at elevated risk of developing different types of cancer later in life for several interconnected reasons. These include shared genetic risk factors, side effects from cancer treatments, and natural fluctuations or treatment-related hormonal changes. The risk is particularly pronounced for those with hormone receptor-negative breast cancers, which don't depend on estrogen or progesterone for growth and carry an even higher subsequent cancer risk than hormone receptor-positive cancers.

One especially concerning pattern is "late recurrences," where secondary breast cancers arise years or even decades after the original tumor has been treated. This means survivors need ongoing vigilance well into the future.

What Are Multicancer Early Detection Blood Tests, and How Do They Work?

Over the past decade, researchers have developed multicancer early detection (MCED) blood tests that can screen for many cancers simultaneously. These tests work by analyzing blood samples for cancer-associated proteins and patterns in circulating cell-free DNA, which are fragments of DNA released into the bloodstream by cancer cells. The advantage is that a single blood draw can potentially detect signals of multiple cancer types, rather than requiring separate screening tests for each cancer.

The Fred Hutch study, led by Dr. Kemal Gogebakan in the lab of Dr. Ruth Etzioni, used mathematical modeling to simulate what would happen if breast cancer survivors received annual MCED blood testing. The researchers created virtual scenarios for hundreds of thousands of women between ages 50 and 74, comparing outcomes for breast cancer survivors with hormone receptor-positive cancers, hormone receptor-negative cancers, and age-matched women with no cancer history.

What Did the Study Find About Cancer Prevention Benefits?

The results were striking. Across every scenario tested, multicancer screening reduced the rate of late-stage cancer diagnoses, and the benefit was consistently greater for breast cancer survivors than for average-risk women. In the most optimistic scenario, survivors with hormone receptor-negative breast cancers saw up to 111 late-stage diagnoses prevented per 100,000 person-years, representing a 26% relative reduction. By comparison, average-risk women saw 84 late-stage diagnoses prevented per 100,000 person-years, a 20% reduction.

The study tracked 16 different cancer types and identified which cancers drove the most benefit from screening:

• Lung cancer: Accounted for 34-38% of the late-stage diagnoses prevented across all groups, making it the single largest contributor to screening benefit
• Colorectal cancer: Contributed 14-16% of the late-stage reduction, representing the second-most significant benefit
• Ovarian cancer: Contributed about 10-11% of the benefit in hormone receptor-negative survivors, nearly double its contribution in hormone receptor-positive survivors and average-risk women, since hormone receptor-negative breast cancer is specifically associated with elevated ovarian cancer risk

The ovarian cancer finding was particularly noteworthy. Hormone receptor-negative breast cancer survivors have a genuinely elevated risk of ovarian cancer that hasn't been widely recognized, underscoring the importance of considering survivor subgroups separately rather than treating all survivors as one group.

How Could Survivors Benefit From Targeted Screening Approaches?

The researchers noted that a more targeted approach, focusing specifically on lung, colorectal, and ovarian screening, might capture most of the benefit from multicancer blood testing with even higher per-cancer sensitivity. This could make screening more efficient and potentially more cost-effective.

"This is one of the first studies to quantify the potential benefit of multicancer screening in a high-risk population. Most modeling work in this field, including our own prior works, has focused on average-risk individuals. Breast cancer survivors represent an important high-risk group in which multicancer screening may have distinct clinical value," explained Dr. Kemal Gogebakan.

Dr. Kemal Gogebakan, Researcher at Fred Hutch Cancer Center

Currently, survivorship guidelines for breast cancer focus almost entirely on watching for recurrence or a new breast tumor through mammography. There is very limited guidance on screening for other subsequent malignancies. In the absence of standardized recommendations, some survivors are already accessing blood-based multicancer early detection tests on their own, without clear evidence to guide their decisions or their oncologists' recommendations.

What Should Breast Cancer Survivors Know About Their Cancer Risk?

The key takeaway from this research is that breast cancer survivors should be aware of their elevated risk for developing new primary cancers, even many years after their initial diagnosis. This awareness is the first step toward discussing screening options with their healthcare providers.

"The significant contribution of this work is that it affirms and estimates the extent to which the benefits of multicancer screening in breast cancer survivors may exceed those in the average-risk population. Not all breast cancer survivors are the same: hormone receptor-negative survivors have a higher risk of new primary cancers, and our projections show they stand to gain more from multicancer screening. We hope our study can inform future survivorship guidelines," stated Dr. Gogebakan.

Dr. Kemal Gogebakan, Researcher at Fred Hutch Cancer Center

The researchers plan to extend their adaptable framework to other high-risk survivor populations, including childhood cancer survivors and colorectal cancer survivors. This suggests that the benefits of multicancer early detection blood testing may extend beyond breast cancer survivors to other groups with elevated cancer risk.

For now, the study provides important evidence that could shape future survivorship guidelines and help oncologists and survivors make more informed decisions about screening. The message is clear: surviving cancer doesn't mean the conversation about prevention ends. It may, in fact, be just beginning.